Navigation Links
NeoVista Presents One Year Data on Novel Wet AMD Therapy at Macula Society
Date:3/28/2008

Data Analysis Shows Promise of Epiretinal Brachytherapy as NeoVista

Progresses with Phase III CABERNET Study

PALM BEACH, Fla., March 28 /PRNewswire/ -- NeoVista, Inc. released today to the eye community updated results from a one-year feasibility study of the company's novel epiretinal brachytherapy for the wet form of age-related macular degeneration (AMD) at the 31st Annual Macula Society Meeting in Palm Beach, Florida. The promising data from the study, which was initiated by NeoVista to test the efficacy and safety of their novel therapy when used in conjunction with Avastin(R) (bevacizumab), showed a marked improvement in mean visual acuity.

In the ongoing nonrandomized, multicenter feasibility study, 34 subjects with predominantly classic, minimally classic, or occult (with no classic) choroidal neovascularization (CNV) received a single 24 Gy treatment of NeoVista's epiretinal brachytherapy in combination with two injections of Avastin, one dose prior to or at the time of radiation delivery and another one month later, depending on which arm of the trial the patient was enrolled in.

After 12 months of follow-up on 33 of the trial participants, subjects had experienced a mean improvement in visual acuity of 10 letters using the Early Treatment Diabetic Retinopathy Study (ETDRS) test; 94 percent of patients lost fewer than 15 letters, 39 percent gained 15 or more letters, and 12 percent gained 30 or more letters. 76 percent of the patients in the study did not require additional injections of Avastin throughout the year.

Most adverse events were related to the vitrectomy procedure (retinal tear, retinal detachment, subretinal hemorrhage, and vitreous hemorrhage). No events related to radiation toxicity have been reported to date.

Jeffrey S. Heier, MD, a retinal specialist, partner at Ophthalmic Consultants of Boston and a consultant for NeoVista, presented the one-year data obtained from trial participants (mean age, 72 years) who enrolled from June 2006 to April 2007 at two centers in Brazil and one in Mexico.

"As more data are collected and analyzed surrounding this one-time surgical procedure, we're continuing to see the potential of the concomitant approach to treat wet AMD," said Dr. Heier. "Unlike previous attempts with radiation therapy, NeoVista has developed a means of delivering targeted beta radiation to choroidal neovascular membranes with minimal penetration, resulting in little effect on the surrounding healthy tissue."

In contrast to other forms of radiation therapy for wet AMD, NeoVista's approach delivers the peak dose of energy directly to the lesion without irreparably damaging the normal retinal vasculature. Utilizing strontium 90, the focused energy is delivered to a target area up to 3 mm in depth and up to 5.4 mm in diameter. Importantly for patients, the systemic exposure to radiation is minimal, as the effective dose to the entire body from NeoVista's epiretinal device is less than that from a typical chest x-ray.

"We've seen a significant amount of promise so far with epiretinal brachytherapy and we're excited to see the ultimate potential of the therapy when evaluated in our definitive Phase III trial," said John N. Hendrick, President and CEO of NeoVista. "Patients will finally be able to have access to a treatment for wet AMD that not only has the possibility of restoring their vision, but also saving them money and alleviating the difficulties of current treatment regimens for all involved -- patients, caretakers and physicians."

The CABERNET (CNV Secondary to AMD Treated with BEta RadiatioN Epiretinal Therapy) trial is a multicenter, randomized, controlled study that will enroll 450 subjects at clinical centers worldwide. The study will evaluate the safety and efficacy of NeoVista's epiretinal beta radiation therapy delivered concomitantly with the FDA-approved antiangiogenic therapy Lucentis(R) (ranibizumab) versus Lucentis alone.

About NeoVista, Inc.

NeoVista, Inc. is a privately held development-stage medical device company based in Fremont, California. NeoVista's epiretinal beta radiation therapy is currently being studied in a definitive Phase III clinical study to support eventual filing for regulatory approval to market the product in the United States. For more information about the company, the clinical trial or this novel wet AMD therapy, please visit the company's Web site at http://www.neovistainc.com .


'/>"/>
SOURCE NeoVista, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. NeoVista, Inc. Presents New Data on Its Novel Wet AMD Therapy at AAO
2. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
3. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
4. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
5. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
6. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
7. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
8. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
9. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
10. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
11. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... 2017 Eli Lilly and Company (NYSE: ... INCY ) announced today that the U.S. Food and ... the new drug application (NDA) for investigational baricitinib, a ... severe rheumatoid arthritis (RA). The NDA for baricitinib was ... The FDA extended the action date to allow time ...
(Date:1/13/2017)... -- Wichita Laser Clinic at Healthy Life ... Wichita, Kansas featuring the Astanza Revolution ... rejuvenation, getting rid of unwanted tattoos, killing toenail fungus, ... "Since being in the aesthetics industry, I have ... for laser tattoo removal and other popular cosmetic ...
(Date:1/13/2017)... , Jan. 12, 2017   JDRF ... diabetes (T1D) research, is pleased to announce that ... the Centers for Medicare & Medicaid Services (CMS) ... by the FDA for use in making diabetes ... step toward making them eligible for coverage under ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... ... NexTec Group has been selected as a member of the Bob Scott’s VAR ... field of midmarket financial software. , Members of the VAR Stars were selected based ... on revenue and those firms chosen represent a wide range of size and many ...
(Date:1/15/2017)... ... January 15, 2017 , ... ... Outreach is a program that strives to better communities around the world by ... community. It also provides the opportunity for team members to become involved in ...
(Date:1/15/2017)... ... January 15, 2017 , ... Accreditation ... achieved accreditation for its specialty care services. Albertsons Companies is the largest ... care service for pharmacy patients. , Accreditation by ACHC reflects Albertsons Companies’ dedication ...
(Date:1/15/2017)... Santa Rosa, CA (PRWEB) , ... January 15, ... ... to nominate their choice of best physicians in eight Bay Area counties for ... selected by the healthcare research company managing the award process. Results were announced ...
(Date:1/15/2017)... ... January 15, 2017 , ... The Gravity Vault Indoor Rock ... Pennsylvania. As construction wraps up on the 14,000+ square foot climbing gym, the owners ... location, including three in New Jersey and two in New York. With this being ...
Breaking Medicine News(10 mins):